ALL

Summary from the TLDR newsletter

A New Zealand-based startup, Kimer Med, is trying to develop a broad-spectrum antiviral. Its current strategy involves targeting a factor in human cells to attack a wide variety of viruses. Kimer's technology triggers a process that kills targeted cells upon detection. While it has shown promise in the lab, the company still has to prove that it works in animals and humans. A broad-spectrum antiviral would save tens of millions of lives and trillions of dollars over the coming decades.